According to the deep-dive market assessment study by Growth+ Reports, the global allergic bronchopulmonary aspergillosis therapeutics market is expected to witness a CAGR of ~5.3% from 2022 to 2030.
The rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pneumonia is the main driver of the global market for therapies for allergic bronchopulmonary aspergillosis. Another significant factor fueling the growth of the global market is the existence of a robust product pipeline for ABPA. The total amount spent on R&D to develop novel aspergillosis treatments has grown. The major market players are also using acquisition and partnership strategies to produce new medications, accelerating global expansion. Similarly, the ongoing introduction of new treatments and growing public awareness of the need to treat allergic bronchopulmonary aspergillosis are promoting the expansion of the global allergic bronchopulmonary aspergillosis therapeutics market. The main factors limiting the growth of the global allergic bronchopulmonary aspergillosis therapeutics market, however, are the stringent regulations for drug approvals and the rise of generic competition. Additionally, other challenges impeding the global allergic bronchopulmonary aspergillosis market growth include side effects of corticosteroids, such as fluid retention, causing swelling in lower legs, high blood pressure, and rising resistance to antifungal drugs.
The rising prevalence of diseases such as asthma and cystic fibrosis is the major driving factor of the market, as allergic bronchopulmonary aspergillosis (ABPA) is more commonly found in such patients. According to the Centers for Disease Control and Prevention (CDC), around 1% to 15% of patients with cystic fibrosis are affected by allergic bronchopulmonary aspergillosis globally. Similarly, in a study conducted by the same source, approximately 2.5% of people with asthma have allergic bronchopulmonary aspergillosis, which is around 4.8 million worldwide.
A robust product pipeline for allergic bronchopulmonary aspergillosis is one of the significant factors propelling the growth of the global market. There are a large number of promising drugs which are currently in phase 3 of the clinical trials. For instance, Regeneron Pharmaceuticals, in collaboration with Sanofi, is studying the efficacy and safety of dupilumab in participants with allergic bronchopulmonary aspergillosis, which is showing positive results in phase 3 of clinical trials. Similarly, Scynexis, Inc. is assessing ibrexafungerp (SCY-078) in patients 18 years of age and above for ABPA, which is in phase 3 of clinical trials.
The major companies are adopting strategies such as acquisition and collaboration to develop novel drugs for ABPA. For instance, in April 2021, Pfizer Inc. acquired Amplyx Pharmaceuticals, Inc., a privately held company dedicated to developing therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for treating invasive fungal infections. Pfizer has secured ownership of Amplyx's early-stage pipeline, including potential antiviral (MAU868) and antifungal (APX2039) therapies. Moreover, PULMATRiX, Inc. has collaborated with Cipla for the development of PUR1900 antifungal program for allergic bronchopulmonary aspergillosis (ABPA) treatment, which is in phase 2 of the clinical trials. At one-tenth, the dose, PUR1900 (itraconazole formulated with iSPERSETM) provided approximately 50-fold higher lung exposure and 85-fold lower plasma exposure than Sporanox, the currently available oral formulation of itraconazole.
Conversely, there are many complications are associated with corticosteroids, such as hyperglycemia, Cushing’s disease, weight gain, and osteoporosis. Similarly, prolonged use of oral corticosteroids can cause elevated pressure in the eyes (glaucoma) and clouding of the lens in one or both eyes (cataracts). Thus, this is one factor restricting the growth of the global allergic bronchopulmonary aspergillosis therapeutics market.
Asia Pacific is projected to be the fastest-growing region of the global allergic bronchopulmonary aspergillosis therapeutics market. The region's high growth can mainly be attributed to factors such as the rising cases of fungal infection as most common mold infection among immunocompromised people in the Asia-Pacific region is still invasive aspergillosis (IA). Moreover, the healthcare infrastructure is rapidly developing in the region, and the major companies are also haavily investing due to favorable policy by the domestic governments. Additionally, the rising geriatric population in the region which more prone to asthma.
Some of the prominent players operating in the global allergic bronchopulmonary aspergillosis therapeutics market are Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Astellas Pharma US Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, F2G Ltd., Regeneron Pharmaceuticals Inc., Biosergen AB, Zambon SpA, PULMATRiX Inc., Scynexis Inc., and Pulmocide Ltd., among others.